Physicians stand to earn big money when signing up patients for drug trials. And lately, some of those trials have been ...

Scientists at the Herbert Irving Comprehensive Cancer Center (HICCC) have discovered a key mechanism that makes prostate cancer cells resistant to the latest drugs used to treat them. Their findings, ...

Clinicians from Fox Chase Cancer Center at Temple University Health share their highlights from the Society of Urologic ...

As clinical research evolves, disruptive trial designs are reshaping how oncology advances. By integrating novel ...

A closer look at phase 3 data on BioNTech and OncoC4’s anti-CTLA-4 antibody has shown the efficacy that excited analysts last ...

Shares of Janux Therapeutics slumped nearly 50% on Tuesday as investors reacted to limited disclosure in the company's early-stage study update for its prostate cancer treatment. The lead candidate, ...

Janux posts what it called ‘positive trial data’ for its novel treatment in patients with late-stage prostate cancer.

In early December 2025, Janux Therapeutics reported updated interim Phase 1 data for JANX007 in metastatic castration-resistant prostate cancer, showing anti-tumor activity with partial responses in ...

Detailed price information for Amicus Therapeutics (FOLD-Q) from The Globe and Mail including charting and trades.